Key statistics
As of last trade, Savara Inc (YB4P:DEU) traded at 4.10, 38.51% above the 52 week low of 2.96 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.94 |
---|---|
High | 4.10 |
Low | 3.94 |
Bid | 4.12 |
Offer | 4.20 |
Previous close | 3.98 |
Average volume | 388.89 |
---|---|
Shares outstanding | 164.60m |
Free float | 156.82m |
P/E (TTM) | -- |
Market cap | 763.75m USD |
EPS (TTM) | -0.4317 USD |
Data delayed at least 15 minutes, as of Sep 19 2024.
More ▼
Press releases
- Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
- Savara Announces New Employment Inducement Grant
- Savara to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Savara to Present New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2024
- Savara Reports Second Quarter 2024 Financial Results and Provides Business Update
- Savara Announces Pricing of $100.0 Million Underwritten Offering of Common Stock
- Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
- Savara to Host Investor Call to Discuss Top Line Results From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
More ▼